Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa

INTRODUCTION: A reversal agent for factor Xa (FXa) inhibitors, andexanet alfa, was Food and Drug Administration approved without extensive study of clinical effectiveness, due to an overwhelming demand for FXa inhibitor reversal. In this study, we aimed to describe patient selection, clinical effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Nederpelt, Charlie J., Naar, Leon, Sylvester, Katelyn W., Barra, Megan E., Roberts, Russel J., Velmahos, George C., Kaafarani, Haytham M. A., Rosenthal, Martin G., King, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
HAEMOSTASIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589264/
https://www.ncbi.nlm.nih.gov/pubmed/32738161
http://dx.doi.org/10.1111/jth.15031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589264/
https://www.ncbi.nlm.nih.gov/pubmed/32738161
http://dx.doi.org/10.1111/jth.15031

Ejemplares similares